83.50

0.31% 0.26

After Hours: 83.92 0.42 +0.50%

Bright Minds Biosciences Inc (DRUG)

Overview News Price History Discussions Forecast Stock Split

Bright Minds Biosciences Inc stock is traded at $83.50, with a volume of 280.25K. It is up +0.31% in the last 24 hours and down -7.38% over the past month. Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Previous Close:

$83.24

Open:

$83.37

24h Volume:

280.25K

Relative Volume:

1.62

Market Cap:

$817.23M

Revenue:

Net Income/Loss:

$-14.23M

P/E Ratio:

-43.05

EPS:

-1.9396

Net Cash Flow:

$-9.44M

1W Performance:

+7.78%

1M Performance:

-7.38%

6M Performance:

+42.52%

1Y Performance:

+176.31%

1-Day Range:

$81.61

$86.56

1-Week Range:

$72.44

$86.56

52-Week Range:

$23.18

$123.75

Bright Minds Biosciences Inc Stock (DRUG) Company Profile

Name

Bright Minds Biosciences Inc

Sector

Healthcare (1108)

Industry

Biotechnology (618)

Phone

Address

Employee

Twitter

Next Earnings Date

2026-05-21

Latest SEC Filings

DRUG's Discussions on Twitter

Compare DRUG vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
DRUG Bright Minds Biosciences Inc	83.50	814.68M	0	-14.23M	-9.44M	-1.9396
VRTX Vertex Pharmaceuticals Inc	434.52	110.03B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	638.88	67.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	806.46	50.76B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	297.45	40.12B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	151.56	32.68B	742.00K	-1.37B	-1.07B	-7.0731

Bright Minds Biosciences Inc Stock (DRUG) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-13-26	Initiated	Jefferies	Buy
Sep-08-25	Initiated	BTIG Research	Buy
May-13-25	Initiated	TD Cowen	Buy
May-07-25	Initiated	Chardan Capital Markets	Buy
Jan-23-25	Initiated	Piper Sandler	Overweight
Jan-10-25	Initiated	Cantor Fitzgerald	Overweight
Jan-10-25	Initiated	H.C. Wainwright	Buy
Nov-26-24	Initiated	Robert W. Baird	Outperform

View All

Bright Minds Biosciences Inc Stock (DRUG) Latest News

May 24, 2026

Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline - AOL.com

May 24, 2026

May 22, 2026

B Group Discloses New Position in Bright Minds Biosciences - HarianBasis.co

May 22, 2026

May 21, 2026

Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline - The Motley Fool

May 21, 2026

Bright Minds Biosciences Stock Jumps After $220 Piper Sandler Call—What DRUG Traders Are Watching - Bez Kabli

May 21, 2026

May 20, 2026

Piper Sandler raises Bright Minds stock price target on program progress - Investing.com UK

May 20, 2026

Piper Sandler Maintains Bright Minds Biosciences(DRUG.US) With Buy Rating, Raises Target Price to $220 - Moomoo

May 20, 2026

Piper Sandler raises Bright Minds stock price target on program progress By Investing.com - Investing.com South Africa

May 20, 2026

Bright Minds Biosciences Boosts Cash Reserves as R&D Losses Widen in Q2 2026 Filing - TipRanks

May 20, 2026

May 19, 2026

[6-K] BRIGHT MINDS BIOSCIENCES INC. Current Report (Foreign Issuer) | DRUG SEC FilingForm 6-K - Stock Titan

May 19, 2026

May 15, 2026

Vestal Point (DRUG) and Ryan Wilder report 492,319 shares, 5% stake - Stock Titan

May 15, 2026

Janus Henderson (DRUG) discloses 1.28M shares, 13.1% stake - Stock Titan

May 15, 2026

Janus Henderson Group (DRUG) discloses 1.28M shares, 13.1% stake - Stock Titan

May 15, 2026

May 13, 2026